Opendata, web and dolomites

ThyroTrust

A novel reliable diagnostic device to avoid unnecessary thyroid surgery

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ThyroTrust project word cloud

Explore the words cloud of the ThyroTrust project. It provides you a very rough idea of what is the project "ThyroTrust" about.

influences    quality    malignancy    300    reveal    business    47    prevalence    measured    panel    price    variations    aspiration    procedure    fine    fna    diagnosis    idea    first    performed    life    90    15    histology    postoperative    thyroidectomy    lesion    positive    category    planning    thyroid    80    classified    abolishment    virtually    either    26    fnac    market    rearrangements    estimation    adverse    proposing    effect    types    ing    genes    tool    forcing    ce    diagnostics    indeterminate    needle    time    66    considerable    clinically    expression    validated    44000    financial    route    plan    risk    gene    million    surgery    feasibility    sequencing    30    cos    replacement    introduce    complications    unnecessary    addressable    nodules    cytological    italy    scope    outcome    cytology    correct    social    clinical    organization    patients    surgical    frequent    hormone    kit    opportunity    diagnostic    generation    negative    strategy    lt    manufacturing    ipr    surgeries    benign    ivd    malignant       740    thyrotrust    prudentially    search    innovation    cancer   

Project "ThyroTrust" data sheet

The following table provides information about the project.

Coordinator
GENOMNIA SRL 

Organization address
address: CORSO MAGENTA 56
city: MILANO
postcode: 20123
website: www.genomnia.com

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Project website http://www.genomnia.it
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2015
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-02-01   to  2016-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    GENOMNIA SRL IT (MILANO) coordinator 50˙000.00

Map

 Project objective

Fine needle aspiration cytology (FNAC) is the best procedure for a timely and reliable diagnosis of either a benign or malignant thyroid lesion. However, the management of patients with indeterminate cytology (10-26%) is a frequent clinical and social problem, as this cytological category is associated with a 15 to 30% prevalence of malignancy, forcing most of these patients to diagnostic surgery. However, for the 80% of these patients the surgery is unnecessary as the postoperative histology reveal a benign lesion. The negative social and financial consequences of this approach are relevant in Europe (44000/year thyroidectomy only in Italy) as well as the adverse influences on the quality of life of the patients due to surgical complications and hormone replacement. We will introduce in the market the first clinically validated CE-IVD targeted Next Generation Sequencing diagnostic kit ThyroTrust for the correct diagnosis of thyroid nodules with indeterminate cytology. Our kit is the first to include a considerable number of variations in 47 genes, 66 types of rearrangements and 8 gene expression level measured at the same time and associated with malignant outcome. This will avoid diagnostic surgery if a risk of malignancy <5%. In the scope of the feasibility study we will assess: - Technology innovation opportunity and business idea - Development planning and partner search - IPR, quality, organization and manufacturing route - GO-TO-MARKET strategy and business plan 740,000 FNA are performed in Europe, so the addressable market, with an end-user price/kit of 300€, is over €50 Million/year. Prudentially, market estimation considers only FNA results classified as “indeterminate cytology”. The same approach could be evaluated and adopted for other cancer diagnostics, proposing a similar gene panel kit on the market. The positive effect resulting from such diagnostic tool can virtually lead to the abolishment of 90% of unnecessary surgeries and related cos

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "THYROTRUST" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "THYROTRUST" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

INADVANCE (2019)

Patient-centred pathways of early palliative care, supportive ecosystems and appraisal standard

Read More  

INTE-AFRICA (2019)

Integrating and decentralising diabetes and hypertension services in Africa

Read More  

SHIGETECVAX (2019)

Early clinical development of a live, attenuated combination vaccine against Shigella and ETEC diarrhoea

Read More